Lecithin vesicles for topical delivery of diclofenac

被引:62
作者
Boinpally, RR
Zhou, SL
Poondru, S
Devraj, G
Jasti, BR
机构
[1] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[2] Kakatiya Univ, Coll Pharm, Warangal 506009, Andhra Pradesh, India
[3] Univ Pacific, Sch Pharm, Stockton, CA 95211 USA
关键词
topical diclofenac; lecithin vesicle; rheumatic disease; actinic keratosis;
D O I
10.1016/S0939-6411(03)00143-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Skin penetration of topically applied diclofenac is important for the treatment of rheumatic diseases and actinic keratoses. We have studied the permeation of diclofenac across human cadaver epidermis in-vitro from four lecithin vesicle formulations and a few marketed semi-solid preparations. The lecithin vesicle formulations were prepared by dissolving the lipid contents (lecithin and sodium cholate) in a 1:1 mixture of methanol-chloroform, evaporating the solvents under vacuum, and hydrating the lipid layer with the drug solution in water or 10% ethanol. The vesicles were sonicated for 5 min to reduce the vesicle size and their size and Zeta potential were characterized. The cumulative amount and maximum flux of diclofenac was 69.7 +/- 40.3 mug and 4.77 +/- 3.16 mug/h cm(2) from lecithin vesicles containing sodium cholate and 10% ethanol, and is the highest of all formulations studied. The cumulative amount and mean maximum flux obtained from other formulations were in the range of 2.46 +/- 1.98-29.9 +/- 10.1 mug and 0.53 +/- 0.46-3.61 +/- 0.86 mug/h cm(2). Based on the results, lecithin vesicles of diclofenac appear to be advantageous for the topical delivery of diclofenac. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:389 / 392
页数:4
相关论文
共 9 条
[1]   Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin [J].
Cevc, G ;
Gebauer, D ;
Stieber, J ;
Schätzlein, A ;
Blume, G .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1998, 1368 (02) :201-215
[2]   New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes [J].
Cevc, G ;
Blume, G .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1514 (02) :191-205
[3]   DIRECT-CURRENT IONTOPHORETIC TRANSDERMAL DELIVERY OF PEPTIDE AND PROTEIN DRUGS [J].
CHIEN, YW ;
SIDDIQUI, O ;
SHI, WM ;
LELAWONGS, P ;
LIU, JC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (05) :376-383
[4]  
FIGUERAS A, 1994, EUR J CLIN PHARMACOL, V47, P297
[5]   Oral versus topical NSAIDs in rheumatic diseases - A comparison [J].
Heyneman, CA ;
Lawless-Liday, C ;
Wall, GC .
DRUGS, 2000, 60 (03) :555-574
[6]   Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes [J].
Paul, A ;
Cevc, G ;
Bachhawat, BK .
VACCINE, 1998, 16 (2-3) :188-195
[7]  
SANTOS SRCJ, 1992, BRAZ J MED BIOL RES, V25, P125
[8]  
Schatzlein A, 1998, BRIT J DERMATOL, V138, P583
[9]   DICLOFENAC SODIUM - A REAPPRAISAL OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY [J].
TODD, PA ;
SORKIN, EM .
DRUGS, 1988, 35 (03) :244-285